ライフサイエンスコーパス: MRSA infection

1 atients is associated with increased risk of MRSA infection.

2 ion contributed to lower rates of nosocomial MRSA infection.

3 coccus aureus (MRSA) have increased risk for MRSA infection.

4 %, and only 1 of 5 deaths was related to the MRSA infection.

5 anscriptional regulators in the pathology of MRSA infection.

6 nce and leads to susceptibility to secondary MRSA infection.

7 n SEB-neutralizing mAb, is effective against MRSA infection.

8 vivo in a clinically relevant mouse model of MRSA infection.

9 anism of host resistance against intradermal MRSA infection.

10 ospital with S. aureus HCAP have evidence of MRSA infection.

11 ally sterile sites in patients with invasive MRSA infection.

12 now an abundant cause of community-acquired MRSA infection.

13 patients had a documented risk factor for CA-MRSA infection.

14 ercent of patients were hospitalized for the MRSA infection.

15 or health problems were not associated with MRSA infection.

16 associated with increased predisposition to MRSA infection.

17 fective therapeutic choice for 'susceptible' MRSA infection.

18 gnificantly increases the risk of subsequent MRSA infection.

19 riaxone/Cefotaxime against highly pathogenic MRSA infection.

20 ancomycin for the treatment of intracellular MRSA infection.

21 eutic strategies to address the challenge of MRSA infection.

22 ew and effective antimicrobial agent against MRSA infection.

23 he protective host defense against recurring MRSA infection.

24 ng bacterial burden in a mouse model of skin MRSA infection.

25 fold increase in the incidence of subsequent MRSA infection.

26 thletes and estimate the risk for subsequent MRSA infection.

27 directly contributes to pathogenicity during MRSA infection.

28 for the antibiotic selected for treatment of MRSA infection.

29 ive MSSA infection and infants with invasive MRSA infection.

30 novel approaches to address the challenge of MRSA infection.

31 a suitable target for preventing or treating MRSA infection.

32 pment of an antivirulence agent for managing MRSA infections.

33 timal bacterial clearance during respiratory MRSA infections.

34 ime trends, and long-term risk of subsequent MRSA infections.

35 MRSA) infections were discriminated from non-MRSA infections.

36 of best practice for treating patients with MRSA infections.

37 nt and positive immunomodulatory role during MRSA infections.

38 of the MRSA bundle on health care-associated MRSA infections.

39 future prophylaxis or new treatments for CA-MRSA infections.

40 expressed during superficial and invasive CA-MRSA infections.

41 m children with active known or suspected CA-MRSA infections.

42 screening or reporting in efforts to reduce MRSA infections.

43 ed in 2001, accounted for 82.1% (412/502) of MRSA infections.

44 iant of PVL that is strongly associated with MRSA infections.

45 tics may represent a novel approach to treat MRSA infections.

46 e impact of combination therapy for invasive MRSA infections.

47 Six strain types accounted for 88.2% of all MRSA infections.

48 miology of America for control of nosocomial MRSA infections.

49 and have previously been associated with CA-MRSA infections.

50 administered to 206 trainees, 22 of whom had MRSA infections.

51 be effective in a significant proportion of MRSA infections.

52 minant in Chile, a region with high rates of MRSA infections.

53 ainst E. coli; P. aeruginosa; S. aureus; and MRSA infections.

54 art of an alternative treatment strategy for MRSA infections.

55 s to reduce drug resistance and virulence in MRSA infections.

56 ide updated estimates of the excess costs of MRSA infections.

57 ices that are effective at limiting invasive MRSA infections.

58 unct antivirulence therapy for patients with MRSA infections.

59 ctam-avibactam combinations have on treating MRSA infections.

60 among isolates from patients with recurrent MRSA infections.

61 re now available for the treatment of severe MRSA infections.

62 ass of antibiotics holds promise in fighting MRSA infections.

63 o eliminate methicillin-resistant S. aureus (MRSA) infection.

64 methicillin-resistant Staphylococcus aureus (MRSA) infection.

65 methicillin-resistant Staphylococcus aureus (MRSA) infection.

66 mice after methicillin-resistant S. aureus (MRSA) infection.

67 methicillin-resistant Staphylococcus aureus (MRSA) infections.

68 3 (17%) had methicillin-resistant S. aureus (MRSA) infections.

69 methicillin-resistant Staphylococcus aureus (MRSA) infections.

70 methicillin-resistant Staphylococcus aureus (MRSA) infections.

71 eatment for methicillin-resistant S. aureus (MRSA) infections.

72 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections.

73 e methicillin-resistantStaphylococcus aureus(MRSA) infections.

74 methicillin-resistant Staphylococcus aureus (MRSA) infections.

75 a significant reduction in Gram-positive or MRSA infections?

76 Among the 283 MRSA infections, 127 (44.9%) were defined as community-a

77 Of 1100 MRSA infections, 131 (12%) were community-associated and

78 There were 19 cases of MRSA infection (16.5%).

79 2008, there were 21,503 episodes of invasive MRSA infection; 17,508 were health care associated.

80 ay was significantly longer for persons with MRSA infection (33 days vs. 22 days; p=.047).

81 zation than those with clindamycin-resistant MRSA infections (71%; P = 0.042).

82 meticillin-resistant Staphylococcus aureus (MRSA) infections across a region of Scotland.

83 Invasive MRSA infection affects certain populations disproportion

84 egies, we assessed risk factors for invasive MRSA infection after acute-care hospitalizations.

85 to reduced PANX1 function increases risk for MRSA infection after liver transplantation by decreasing

86 pidemiology of and recent trends in invasive MRSA infections among dialysis patients.

87 However, the decreases in invasive MRSA infections among recently discharged patients have

88 methicillin-resistant Staphylococcus aureus (MRSA) infections among hospitalized patients.

89 piloted nanocapturer can successfully locate MRSA infection and accurately distinguish the foci from

90 ) mice significantly (P = 0.011) ameliorated MRSA infection and animal death.

91 neutrophil IRE1a were highly susceptible to MRSA infection and failed to effectively form NETs in th

92 major driver of neutrophil activity against MRSA infection and highlight the importance of IRE1a in

93 Fourteen percent of patients with CA-MRSA infections and 3% of patients with CA-MSSA infectio

94 ng important for the development of invasive MRSA infections and are thus potential targets for antiv

95 drawn from an epidemiological network of CA-MRSA infections and colonizations in northern Manhattan

96 dence rates and estimated number of invasive MRSA infections and in-hospital deaths among patients wi

97 otent antibacterial activity against topical MRSA infections and increase the rate of wound closure r

98 d for nonantibiotic immunotherapies to treat MRSA infections and prevent the spread of antibiotic res

99 Nano-mupirocin for the treatment of invasive MRSA infections and support the further clinical develop

100 A major issue is to identify the sources of MRSA infections and to monitor their epidemic spread.

101 methicillin-resistant Staphylococcus aureus (MRSA) infections and all-cause bloodstream infections.

102 methicillin-resistant Staphylococcus aureus (MRSA) infections and widespread use of vancomycin, MRSA

103 Compared to methicillin-sensitive S. aureus, MRSA infections are associated with greater morbidity an

104 Additionally, CA-MRSA infections are epidemic in some countries.

105 es of antibiotics, and treatment options for MRSA infections are limited.

106 Community-associated MRSA infections are now a common and serious problem.

107 methicillin-resistant Staphylococcus aureus (MRSA) infections are a burden on the health care system.

108 Methicillin-resistant Staphylococcus aureus (MRSA) infections are a global public health problem.

109 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections are encroaching upon nosocomial setting

110 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections are frequently associated with strains

111 methicillin-resistant Staphylococcus aureus (MRSA) infections are increasing and may now involve pers

112 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections are predominantly those affecting skin

113 methicillin-resistant Staphylococcus aureus (MRSA) infections are reported as decreasing, but recent

114 Methicillin-resistant Staphylococcus aureus (MRSA) infections are still difficult to treat, despite t

115 Health-care-associated MRSA infections arise in individuals with predisposing r

116 contrast, many community-associated MRSA (CA-MRSA) infections arise in otherwise healthy individuals

117 The primary outcome was MRSA infection as defined according to Centers for Disea

118 their potential utility in the treatment of MRSA infections as well as in wound healing.

119 methicillin-resistant Staphylococcus aureus (MRSA) infections as a measure to minimize vancomycin-ass

120 rsal surveillance, the prevalence density of MRSA infection at each body site had a statistically sig

121 d the seasonality of community acquired (CA)-MRSA infections at the population level.

122 hereas the annual ratio of CA-MRSA in ocular MRSA infections averaged 66.1% and tended to increase ov

123 methicillin-resistant Staphylococcus aureus (MRSA) infections between 2010 and 2014 primarily reflect

124 Injecting drug users accounted for 49% of CA-MRSA infections but only 19% of the HA-MRSA infections (

125 Vancomycin is used to treat serious MRSA infections, but treatment failures occur despite MR

126 methicillin-resistant Staphylococcus aureus (MRSA) infection, but the molecular mechanism remains unc

127 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections, but there are limited data regarding t

128 ABL treatment stabilized and reduced MRSA infection by greater than 4 orders of magnitude (>9

129 methicillin-resistant Staphylococcus aureus (MRSA) infections by demonstrating that oxacillin can be

130 children in the Midwest suggest that serious MRSA infections can be acquired in the community in rura

131 methicillin-resistant Staphylococcus aureus (MRSA) infection can quickly develop into severe, necroti

132 Additionally, 52% of jail-onset MRSA infections carried this plasmid compared to 14% of

133 Methicillin-resistant Staphylococcus aureus (MRSA) infections cause significant mortality and morbidi

134 Methicillin-resistant Staphylococcus aureus (MRSA) infections cause substantive morbidity and mortali

135 atients with traditional hospital-associated MRSA infections, compared with patients with CA-MRSA inf

136 The restricted treatment options for CA-MRSA infections compound the effect of enhanced virulenc

137 methicillin-resistant Staphylococcus aureus (MRSA) infection continues to rise in many health care se

138 l, particularly if successful hospital-based MRSA infection control programmes are maintained.

139 as, rates of invasive health care-associated MRSA infections decreased among patients with health car

140 Incidence of invasive MRSA infections decreased from 6.5 to 4.2 per 100 dialys

141 Secondary outcomes included MRSA infection determined on the basis of clinical judgm

142 st injection-drug use (43 percent); previous MRSA infection, diabetes, and chronic hepatitis C (21 pe

143 ty-acquired methicillin-resistant S. aureus (MRSA) infections, displays the giant protein Ebh on its

144 activity and favorable clinical response in MRSA infections distinguishes it from other fluoroquinol

145 Six of seven institutions had at least one MRSA infection during the study.

146 1598 in-hospital deaths among patients with MRSA infection during the surveillance period.

147 ubjects were followed for the development of MRSA infection during their ICU stay.

148 of MRSA nasal colonization for ICU-acquired MRSA infections, either lower respiratory tract infectio

149 ese cases underscore the changing profile of MRSA infections, especially in the community-based setti

150 was no difference in clinical resolution of MRSA infection even if the infecting organism was resist

151 cantly increases the severity of bloodstream MRSA infection, even when administered in conjunction wi

152 tic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volu

153 The combination effectively treats MRSA infection, for which many antibiotics (including TZ

154 invasive (from a normally sterile body site) MRSA infections from 2005 through 2008 were evaluated an

155 n 2012 and 2017, the incidence decreased for MRSA infection (from 114.18 to 93.68 cases per 10,000 ho

156 Patients with MRSA infection had a six-fold higher mortality rate and

157 Although MRSA infections had been previously associated with high

158 Optimal outpatient therapy for MRSA infections has yet to be determined, but this matte

159 Although methicillin-resistant S. aureus (MRSA) infection has become increasingly reported, popula

160 hicillin-resistant Staphylococcus aureus (CA-MRSA) infection has been defined as an MRSA infection in

161 Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who do not have

162 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections has become a significant health care ch

163 methicillin-resistant Staphylococcus aureus (MRSA) infections has been occurring for the last 15 year

164 Methicillin-resistant Staphylococcus aureus (MRSA) infections have become common among both hospitali

165 methicillin-resistant Staphylococcus aureus (MRSA) infections have been acquired primarily in nosocom

166 methicillin-resistant Staphylococcus aureus (MRSA) infections have declined over the past decade due

167 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections have spawned efforts to define unique v

168 ed to a lower risk of hospitalization due to MRSA infection (hazard ratio, 0.71; 95% CI, 0.51 to 0.99

169 the "gold standard" of treatment for serious MRSA infections; however, the emergence of less-suscepti

170 roles in immunity to cutaneous and invasive MRSA infection in a mouse model of SSSI.

171 s (CA-MRSA) infection has been defined as an MRSA infection in a patient who lacks specific risk fact

172 combinant Reg3gamma administration 4 h after MRSA infection in alcohol-intoxicated mice rescued USA30

173 pression in donor livers was associated with MRSA infection in human liver transplantation recipients

174 decolonization without screening to prevent MRSA infection in intensive-care unit (ICU) patients.

175 Four recent deaths due to MRSA infection in previously healthy children in the Mid

176 398, may be involved in livestock-associated MRSA infection in the United States.

177 ges and neutrophils, and protected mice from MRSA infection in two model systems.

178 Seasonal variation of MRSA infections in hospital settings has been widely obs

179 iven the high rates of primary and recurring MRSA infections in humans, it appears that antibodies to

180 The rates of health care-associated MRSA infections in ICUs had not changed in the 2 years b

181 nterior nares was a significant predictor of MRSA infections in liver transplant recipients.

182 period, the rates of health care-associated MRSA infections in non-ICUs fell from 0.47 per 1000 pati

183 We evaluated MRSA infections in patients identified from population-b

184 Community-acquired MRSA infections in the absence of identified risk factor

185 sociated MRSA (CA-MRSA) has caused increased MRSA infections in the general population, including chi

186 aureus (MRSA) USA300 is the leading cause of MRSA infections in the United States and has caused an e

187 ities and to estimate the burden of invasive MRSA infections in the United States in 2005.

188 the current community-associated epidemic of MRSA infections in the United States.

189 te information on the scope and magnitude of MRSA infections in the US population is needed.

190 substantial clinical and economic impact of MRSA infections in this population.

191 The rate of subsequent MRSA infections in USA300-positive versus -negative pati

192 ections and methicillin-resistant S. aureus (MRSA) infections in 4 Connecticut metropolitan areas (po

193 methicillin-resistant Staphylococcus aureus (MRSA) infections in children have occurred primarily in

194 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections in patients without traditional risk fa

195 methicillin-resistant Staphylococcus aureus (MRSA) infections in the outpatient setting has led to a

196 methicillin-resistant Staphylococcus aureus (MRSA) infections in the United States have been caused b

197 has been a substantial decrease in invasive MRSA infection incidence among dialysis patients.

198 Whether there have been changes in MRSA infection incidence as these programs become establ

199 independently associated with postdischarge MRSA infection included MRSA colonization (matched odds

200 e being developed primarily for treatment of MRSA infections, including tedizolid, dalbavancin, and o

201 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections, including serious invasive infections

202 The association with CO-PVL-negative MRSA infection increased across quartiles of dairy/veal

203 Notably, the risk of developing MRSA infections increased among colonized hemodialysis p

204 significantly associated with mortality for MRSA infection irrespective of the source of infection o

205 In areas in which community-associated MRSA infection is endemic, empirical treatment of suspec

206 r in combination with mupirocin with risk of MRSA infection is important for studies evaluating alter

207 dominant bacteria species was S. aureus and MRSA infection is increasingly prevalent.

208 -0.90), suggesting that the observed rise in MRSA infections is not due to an ongoing epidemic but dr

209 Methicillin-resistant Staphylococcus aureus (MRSA) infection is a global health care problem.

210 Methicillin-resistant Staphylococcus aureus (MRSA) infection is a serious threat to the public health

211 methicillin-resistant Staphylococcus aureus (MRSA) infections is a priority for infection control per

212 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections is increasing in the United States, and

213 A infections, compared with patients with CA-MRSA infections, is independent of the vancomycin MIC, s

214 The 12 epidemiologically defined CA-MRSA infection isolates were either ST1 (n = 4) or ST8 (

215 Among the CA-MRSA infection isolates, 8 (67%) were PVL(+).

216 %) in the decolonization group; 84.8% of the MRSA infections led to hospitalization.

217 culminate in lysis of neutrophils during CA-MRSA infection may serve as a novel therapeutic interven

218 o have sex with men, and multidrug-resistant MRSA infection might be sexually transmitted in this pop

219 In MRSA infection mouse model, MCL down-regulated the expre

220 ospital discharge than infants with invasive MRSA infections (n = 110).

221 In addition, a substantial proportion of MRSA infections occur after discharge from the hospital.

222 In the per-protocol population, MRSA infection occurred in 98 of 1063 participants (9.2%

223 During the 2003 football season, eight MRSA infections occurred among 5 of the 58 Rams players

224 Traditionally, MRSA infections occurred exclusively in hospitals and we

225 Gram-positive related infections and MRSA infections occurred in 1(1.18%)/0(0%) of Vancomycin

226 Invasive MRSA infections occurred more often at a younger postnat

227 methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in US dialysis patients in 201

228 methicillin-resistant Staphylococcus aureus (MRSA) infection occurs at highly endemic levels in inten

229 of CA-MRSA infections but only 19% of the HA-MRSA infections (odds ratio, 4.2; 95% confidence interva

230 tly associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6.21, 95% CI

231 Inpatients with a history of MRSA infection or colonization enrolled between December

232 adult patients after hospital discharge with MRSA infection or colonization.

233 rgies were associated with increased odds of MRSA infection (OR, 1.44; 95% CI, 1.36-1.53), VRE infect

234 iologic purposes to describe the trend in CA-MRSA infections over time.

235 e impact of combination therapy for invasive MRSA infections.Patients treated with daptomycin plus a

236 primary outcomes were prevalence density of MRSA infections per 1000 occupied bed days (OBDs) in hos

237 Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a major challenge in health care,

238 Methicillin-resistant Staphylococcus aureus (MRSA) infections present a serious challenge because of

239 In order to decrease rates of MRSA infection, preventive efforts need to be directed t

240 The MRSA infection rate across the predischarge and 180-day

241 .7 to 101.6]; P < 0.001) independent of past MRSA infection (relative risk, 2.1 [CI, 1.2 to 3.7]; P =

242 methicillin-resistant Staphylococcus aureus (MRSA) infections remain challenging.

243 y inflammatory response in the lung after CA-MRSA infection remains largely undefined.

244 le data suggest that the optimal therapy for MRSA infections remains unclear.

245 equency or not significantly associated with MRSA infection risk in our population of newly identifie

246 ischarge was similar after invasive MSSA and MRSA infections (risk ratio, 1.19; 95% CI, 0.96-1.49).

247 [95% CI], 3.56 to 10.72; P < 0.0001), prior MRSA infection (RR, 3.97; 95% CI, 1.94 to 8.12; P = 0.00

248 adoptively transferred to burned mice at the MRSA infection site, an abscess formed, and the infectio

249 ntribution of this leukotoxin to invasive CA-MRSA infections such as pneumonia remains controversial.

250 ine and mupirocin led to a 30% lower risk of MRSA infection than education alone.

251 o adhered fully to the regimen had 44% fewer MRSA infections than the education group (hazard ratio,

252 We examined MRSA infections that occurred prior to discharge and at

253 Using a murine model of intradermal MRSA infection, the therapeutic efficacy of synthetic S.

254 d in jails and prisons, but risk factors for MRSA infection there are not known.

255 lso at highest risk for community-associated MRSA infection; these subgroups included individuals wit

256 inal results linked the dramatic increase in MRSA infections to an expanding community reservoir of M

257 We evaluated patients with invasive MRSA infections to assess differences in outcomes betwee

258 In a mouse model of systemic MRSA infection, treatment with M -NDs significantly impr

259 rses of 4 subjects with 3-6 recurrent USA300 MRSA infections, using patient clinical data, including

260 rm (6-20 months) probability of developing a MRSA infection was 19% among colonized hemodialysis pati

261 The predischarge hazard ratio for MRSA infection was 29.6 (95% confidence interval [CI], 2

262 e NPV of MRSA nares screening for ruling out MRSA infection was 96.5%.

263 Lastly, topical clindamycin exposure before MRSA infection was associated with ermC plasmid presence

264 MRSA infection was associated with increased length of s

265 MRSA infection was significantly associated with the lin

266 The hazard of MRSA infection was significantly lower in the decoloniza

267 Mortality in MRSA infection was unchanged (25% group 1; 25% group 2;

268 he incidence rate of hospital-onset invasive MRSA infections was 1.02 per 10,000 population in 2005 a

269 The 2011 national estimated number of MRSA infections was 15 169.

270 methicillin-resistant Staphylococcus aureus (MRSA) infection was 24% and multidrug resistance (MDR) w

271 om sample of patients with culture-confirmed MRSA infection; we oversampled patients from the Geising

272 pendently associated with community-acquired MRSA infection were black race (prevalence ratio, 1.53 [

273 recent culture-positive community-associated MRSA infection were enrolled from 2012 to 2013 at St Lou

274 7 cases of community-associated [correction] MRSA infection were reported, representing between 8 and

275 CA-MRSA infections were associated with a more adverse impa

276 Forty-six (74%) of the 62 MRSA infections were classified as community acquired.

277 Most MRSA infections were health care-associated: 5250 (58.4%

278 Nearly all MRSA infections were inferred to be USA300.

279 Patients with clindamycin-susceptible MRSA infections were less likely (59%) to have nasal col

280 Risk factors for community-acquired MRSA infections were not significantly different from th

281 ents with culture-confirmed, community-onset MRSA infections were recruited for the Household Observa

282 Epidemic foci of CA-MRSA infections were reported in jails and prisons, but

283 of infants who died after invasive MSSA and MRSA infections were similar at 237 of 2474 (9.6%) and 1

284 Population-based data for invasive MRSA infections were used to identify 2 cohorts: (1) non

285 methicillin-resistant Staphylococcus aureus (MRSA) infections were discriminated from non-MRSA infect

286 Severe invasive MRSA infections, which include pneumonia, are difficult

287 tibility testing in 100 of 175 patients with MRSA infection who received antibiotics (57 percent).

288 The inability to contain MRSA infection with beta-lactam antibiotics is a continu

289 these outcomes observed with vancomycin for MRSA infections with elevated vancomycin MIC values.

290 methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibitory concentration (

291 methicillin-resistant Staphylococcus aureus (MRSA) infections with vancomycin MICs of 2 mug/ml and co

292 o current clinical practice for treatment of MRSA infection, with the potential to significantly impr

293 cus aureus (MRSA) clones are responsible for MRSA infections worldwide, and those of different lineag